Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).

Annelot G J van Rossum,Ingrid A M Mandjes,Erik van Werkhoven,Harm van Tinteren,A Elise van Leeuwen-Stok,Petra Nederlof,Johanna E A Portielje,Robbert J van Alphen,Els Platte,Daan van den Broek, Alwin Huitema,Marleen Kok,Sabine C Linn,Hendrika M Oosterkamp

Breast care (Basel, Switzerland)（2021）

引用 3|浏览4

暂无评分

摘要

CC and CC+B are safe first-line regimens for mTNBC and the side effects are consistent with those known for each individual agent. pVEGFR-2 concentration did not predict a bevacizumab PFS benefit.

查看译文

关键词

Bevacizumab,Biomarker trial,Carboplatin-cyclophosphamide,Metastatic triple-negative breast cancer,Paclitaxel,Plasma vascular endothelial growth factor receptor-2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要